Genome-edited Camelina sativa plant lines developed by Yield10 Bioscience,
Inc. using CRISPR-Cas9 for increased oil content has received nonregulated
status from the USDA Animal and Plant Health Inspection Service (USDA
APHIS)'s Biotechnology Regulatory Services (BRS).
Yield10 submitted an "Am I Regulated?" letter to the BRS in May 2018,
requesting confirmation of the regulatory status for Camelina plant lines
containing combinations of genetic changes to increase oil production based
on three gene traits: C3008a, C3008b, and C3009. The response from
USDA-APHIS is published in a letter indicating that the plant lines do not
meet the definition of a regulated article under 7 CFR Part 340. Yield10
believes that this is the first triple genome-edited plant to receive
nonregulated status from USDA-APHIS.
Yield10 has conducted studies in the greenhouse and preliminary results
suggest that the triple-edited Camelina lines may have the potential to
increase oil content and to improve oil quality. Yield10 intends to study
these plant lines in field tests planned for 2019 in the U.S. as part of its
development program to increase oil and seed yield in Camelina and canola
for specialty oils applications.